Alzheimer's disorders (AD), is initiated by cascade of neurotoxic events, that includes oxidative stress, brain iron dysregulation, glutamate excitotoxicity, inflammatory process, neurotxic processing of APP misfolding of proteins Ab?peptide. A significant percentage of AD subjects also suffers from extrapyramidal symptoms (Lewy Body disease). These subjects are benefiting from drugs developed to act on a single molecular target. Such drugs have limited symptomatic activities and current pharmacological approaches are highly limited in their ability to modify the course of the disease, offering incomplete and transient benefit to patients. However, the new therapeutic strategies for neurodegenerative diseases, are those in which drug candidates are designed expressly to act on multiple neuronal and biochemical targets involved in the neurodegenerative process and neurotransmission. Thus, we have developed several molecular entities, as derivatives of our successful anti Parkinson drug, rasagiline (Azilect), namely ladostigil (TVP3326, Phase IIa) and M30 series. These drugs combine two or more of cholinesterase inhibition, brain selective MAO inhibition, iron chelation, inhibitors of glutamate neurotoxicity, anti apoptotic-neuroprotective and neurorestorative activities. Animal behavioral and neurophramacological studies have shown their anti Alzheimer, exhibiting neuroprotective and neurorestorative activities in neuronal cell cultures and in vivo. These properties indicate that multimodal rather than "magic bullets" might serve as an ideal drug for treatment of PD and AD, for which they are being developed.